April 11th 2024
The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
The Prognostic Value of CRP in HCC
May 21st 2014Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing treatment with sorafenib.
Watch
The Future of Treating Head and Neck Cancer
April 14th 2014Hassan Arshad, MD, assistant professor of oncology, head and neck surgeon, Department of Head and Neck Surgery/Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, discusses the future of treating head and neck cancer and the challenges behind treating the disease.
Watch
Photodynamic Therapy in Head and Neck Cancer
March 24th 2014Hassan Arshad, MD, assistant professor of oncology, head and neck surgeon, Department of Head and Neck Surgery/Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, discusses a new study that will be evaluating a new approach to photodynamic therapy in patients with head and neck cancer.
Watch
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
Lenvatinib Meets Primary Endpoint in Phase III Differentiated Thyroid Cancer Study
February 3rd 2014The investigational agent lenvatinib (E7808) met its primary endpoint of progression-free survival (PFS) in the phase III SELECT trial, which compared lenvatinib to placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC),according to Eisai Inc., the company that is developing the agent.
Read More
Hyperfractionated Radiotherapy Demonstrates OS Benefit in HNSCC
October 30th 2013Hyperfractionated radiotherapy demonstrated a superior improvement in overall survival rates compared to standard and accelerated radiotherapy when administered without concomitant chemotherapy in patients with locally advanced HNSCC.
Read More
Uncertain Prognostic Value of BRAF Mutation in Papillary Thyroid Cancer
September 26th 2013Across several studies, the BRAFV600E mutation has been reported to be associated with several negative prognostic clinicopathologic features as well as an increase in overall mortality in patients with papillary thyroid carcinoma (PTC).
Read More